2024
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA AND ALLERGIC RHINITIS GROUPED BY BASELINE BLOOD EOSINOPHIL COUNT: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR
WECHSLER M, CHUPP G, ISRAEL E, CASTRO M, BOBER M, LINDSLEY A, SPAHN J, AMBROSE C. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA AND ALLERGIC RHINITIS GROUPED BY BASELINE BLOOD EOSINOPHIL COUNT: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR. CHEST Journal 2024, 166: a4664-a4680. DOI: 10.1016/j.chest.2024.06.2821.Peer-Reviewed Original ResearchImpact of Atopic Status, Prior Omalizumab Use and Baseline Blood Eosinophil Count Alone and in Combination With Total Serum IgE on Maintenance OCS Reduction Outcomes in Patients With Severe Asthma Treated With Mepolizumab in the REALITI-A Study
Liu M, Chaudhuri R, Chupp G, Heaney L, Lee J, Pilette C, Brusselle G, Alfonso Cristancho R, Zhang L, Howarth P. Impact of Atopic Status, Prior Omalizumab Use and Baseline Blood Eosinophil Count Alone and in Combination With Total Serum IgE on Maintenance OCS Reduction Outcomes in Patients With Severe Asthma Treated With Mepolizumab in the REALITI-A Study. 2024, a5376-a5376. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5376.Peer-Reviewed Original Research
2023
Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps
Chupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Smith S, Sousa A, Mayer B, Chan R, Matucci A. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3504-3512.e2. PMID: 37586475, DOI: 10.1016/j.jaip.2023.08.015.Peer-Reviewed Original ResearchConceptsSevere chronic rhinosinusitisOral corticosteroid doseSystemic corticosteroidsNasal polypsChronic rhinosinusitisCorticosteroid doseSinus surgerySCS useTreatment responseLong-term adverse effectsPlacebo treatment responsePrior sinus surgeryPatient baseline characteristicsBlood eosinophil countsSystemic corticosteroid useMepolizumab efficacyCorticosteroid useWeek 52Baseline characteristicsEosinophil countClinical benefitCare treatmentMepolizumabRhinosinusitisPlacebo
2021
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study
Corren J, Bourdin A, Chupp G, Israel E, Ambrose C, Llanos Ackert J, Kmita K, Cook B, Colice G, Menzies-Gow A. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study. 2021, a1198-a1198. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1198.Peer-Reviewed Original Research